A striking imbalance in share activity emerged from a regulatory filing tied to Advanced Medical Solutions Group Plc, with sales outnumbering purchases by more than three to one.
Investec Bank Plc reported selling 250,000 ordinary shares in Advanced Medical Solutions while purchasing just 70,793 shares during dealings conducted on 27th October 2026.
The disclosure, filed the following day under Rule 8.5 of the UK Takeover Code, highlights the bank’s client-serving trading activity during what appears to be an ongoing offer period.
Investec’s position in this situation carries particular weight given that the bank serves simultaneously as both advisor and joint broker to Advanced Medical Solutions Group Plc.
That dual role places Investec under recognised intermediary status, qualifying it as an exempt principal trader required to make public dealing disclosures under the Takeover Code.
All 250,000 shares sold were transacted at a uniform price of 282.25 pence per unit, reflecting a clean execution across the entire disposal.
The purchase activity was slightly more varied, with 70,793 ordinary shares acquired at prices ranging between 282.05 pence and 282.25 pence per unit.
No derivative transactions of any kind were reported, with cash-settled, stock-settled, and all other dealing categories returning no activity for the period.
Investec confirmed there were no indemnity arrangements, option agreements, or any formal or informal understandings relating to voting rights or future acquisitions connected to the disclosed dealings.
The filing was submitted to a Regulatory Information Service as required, with contact for the disclosure listed as Gary Darch, reachable at the bank’s London offices.
Rule 8.5 disclosures serve as a transparency mechanism during offer periods, requiring exempt principal traders dealing in client-serving capacities to report their activity to the market.
The Panel’s Market Surveillance Unit oversees compliance with these requirements, providing a layer of regulatory oversight designed to protect market integrity during sensitive corporate transactions.
